cPLA2 Is protective against COX inhibitor-induced intestinal damage

David C. Montrose, Krishna Kadaveru, Jillian N M Ilsley, Sierra H. Root, Thiruchanduri V. Rajan, Manish Ramesh, Frank C. Nichols, Bruce T. Liang, Dmitry Sonin, Arthur R. Hand, Simona Zarini, Robert C. Murphy, Glenn S. Belinsky, Masako Nakanishi, Daniel W. Rosenberg

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cytosolic phospholipase A2 (cPLA2) is the rate-limiting enzyme responsible for the generation of prostaglandins (PGs), which are bioactive lipids that play critical roles in maintaining gastrointestinal (GI) homeostasis. There has been a long-standing association between administration of cyclooxygenase (COX) inhibitors and GI toxicity. GI injury is thought to be induced by suppressed production of GI-protective PGs as well as direct injury to enterocytes. The present study sought to determine how pansuppression of PG production via a genetic deletion of cPLA2 impacts the susceptibility to COX inhibitor-induced GI injury. A panel of COX inhibitors including celecoxib, rofecoxib, sulindac, and aspirin were administered via diet to cPLA2-/- and cPLA2+/+ littermates. Administration of celecoxib, rofecoxib, and sulindac, but not aspirin, resulted in acute lethality (within 2 weeks) in cPLA2-/- mice, but not in wild-type littermates. Histomorphological analysis revealed severe GI damage following celecoxib exposure associated with acute bacteremia and sepsis. Intestinal PG levels were reduced equivalently in both genotypes following celecoxib exposure, indicating that PG production was not likely responsible for the differential sensitivity. Gene expression profiling in the small intestines of mice identified drug-related changes among a panel of genes including those involved in mitochondrial function in cPLA2-/- mice. Further analysis of enterocytic mitochondria showed abnormal morphology as well as impaired ATP production in the intestines from celecoxib-exposed cPLA2-/- mice. Our data demonstrate that cPLA2 appears to be an important component in conferring protection against COX inhibitor-induced enteropathy, which may be mediated through affects on enterocytic mitochondria.

Original languageEnglish (US)
Pages (from-to)122-132
Number of pages11
JournalToxicological Sciences
Volume117
Issue number1
DOIs
StatePublished - Jun 18 2010
Externally publishedYes

Fingerprint

Cytosolic Phospholipases A2
Celecoxib
Cyclooxygenase Inhibitors
Prostaglandins
Sulindac
Mitochondria
Aspirin
Wounds and Injuries
Enterocytes
Gene Expression Profiling
Nutrition
Bacteremia
Gene expression
Small Intestine
Intestines
Toxicity
Sepsis
Homeostasis
Genes
Adenosine Triphosphate

Keywords

  • COX inhibitor
  • Cytosolic phospholipase A
  • Intestine
  • Mitochondria

ASJC Scopus subject areas

  • Toxicology

Cite this

Montrose, D. C., Kadaveru, K., Ilsley, J. N. M., Root, S. H., Rajan, T. V., Ramesh, M., ... Rosenberg, D. W. (2010). cPLA2 Is protective against COX inhibitor-induced intestinal damage. Toxicological Sciences, 117(1), 122-132. https://doi.org/10.1093/toxsci/kfq184

cPLA2 Is protective against COX inhibitor-induced intestinal damage. / Montrose, David C.; Kadaveru, Krishna; Ilsley, Jillian N M; Root, Sierra H.; Rajan, Thiruchanduri V.; Ramesh, Manish; Nichols, Frank C.; Liang, Bruce T.; Sonin, Dmitry; Hand, Arthur R.; Zarini, Simona; Murphy, Robert C.; Belinsky, Glenn S.; Nakanishi, Masako; Rosenberg, Daniel W.

In: Toxicological Sciences, Vol. 117, No. 1, 18.06.2010, p. 122-132.

Research output: Contribution to journalArticle

Montrose, DC, Kadaveru, K, Ilsley, JNM, Root, SH, Rajan, TV, Ramesh, M, Nichols, FC, Liang, BT, Sonin, D, Hand, AR, Zarini, S, Murphy, RC, Belinsky, GS, Nakanishi, M & Rosenberg, DW 2010, 'cPLA2 Is protective against COX inhibitor-induced intestinal damage', Toxicological Sciences, vol. 117, no. 1, pp. 122-132. https://doi.org/10.1093/toxsci/kfq184
Montrose DC, Kadaveru K, Ilsley JNM, Root SH, Rajan TV, Ramesh M et al. cPLA2 Is protective against COX inhibitor-induced intestinal damage. Toxicological Sciences. 2010 Jun 18;117(1):122-132. https://doi.org/10.1093/toxsci/kfq184
Montrose, David C. ; Kadaveru, Krishna ; Ilsley, Jillian N M ; Root, Sierra H. ; Rajan, Thiruchanduri V. ; Ramesh, Manish ; Nichols, Frank C. ; Liang, Bruce T. ; Sonin, Dmitry ; Hand, Arthur R. ; Zarini, Simona ; Murphy, Robert C. ; Belinsky, Glenn S. ; Nakanishi, Masako ; Rosenberg, Daniel W. / cPLA2 Is protective against COX inhibitor-induced intestinal damage. In: Toxicological Sciences. 2010 ; Vol. 117, No. 1. pp. 122-132.
@article{68699618bf0d4e64a89a9da4fe1f53dd,
title = "cPLA2 Is protective against COX inhibitor-induced intestinal damage",
abstract = "Cytosolic phospholipase A2 (cPLA2) is the rate-limiting enzyme responsible for the generation of prostaglandins (PGs), which are bioactive lipids that play critical roles in maintaining gastrointestinal (GI) homeostasis. There has been a long-standing association between administration of cyclooxygenase (COX) inhibitors and GI toxicity. GI injury is thought to be induced by suppressed production of GI-protective PGs as well as direct injury to enterocytes. The present study sought to determine how pansuppression of PG production via a genetic deletion of cPLA2 impacts the susceptibility to COX inhibitor-induced GI injury. A panel of COX inhibitors including celecoxib, rofecoxib, sulindac, and aspirin were administered via diet to cPLA2-/- and cPLA2+/+ littermates. Administration of celecoxib, rofecoxib, and sulindac, but not aspirin, resulted in acute lethality (within 2 weeks) in cPLA2-/- mice, but not in wild-type littermates. Histomorphological analysis revealed severe GI damage following celecoxib exposure associated with acute bacteremia and sepsis. Intestinal PG levels were reduced equivalently in both genotypes following celecoxib exposure, indicating that PG production was not likely responsible for the differential sensitivity. Gene expression profiling in the small intestines of mice identified drug-related changes among a panel of genes including those involved in mitochondrial function in cPLA2-/- mice. Further analysis of enterocytic mitochondria showed abnormal morphology as well as impaired ATP production in the intestines from celecoxib-exposed cPLA2-/- mice. Our data demonstrate that cPLA2 appears to be an important component in conferring protection against COX inhibitor-induced enteropathy, which may be mediated through affects on enterocytic mitochondria.",
keywords = "COX inhibitor, Cytosolic phospholipase A, Intestine, Mitochondria",
author = "Montrose, {David C.} and Krishna Kadaveru and Ilsley, {Jillian N M} and Root, {Sierra H.} and Rajan, {Thiruchanduri V.} and Manish Ramesh and Nichols, {Frank C.} and Liang, {Bruce T.} and Dmitry Sonin and Hand, {Arthur R.} and Simona Zarini and Murphy, {Robert C.} and Belinsky, {Glenn S.} and Masako Nakanishi and Rosenberg, {Daniel W.}",
year = "2010",
month = "6",
day = "18",
doi = "10.1093/toxsci/kfq184",
language = "English (US)",
volume = "117",
pages = "122--132",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - cPLA2 Is protective against COX inhibitor-induced intestinal damage

AU - Montrose, David C.

AU - Kadaveru, Krishna

AU - Ilsley, Jillian N M

AU - Root, Sierra H.

AU - Rajan, Thiruchanduri V.

AU - Ramesh, Manish

AU - Nichols, Frank C.

AU - Liang, Bruce T.

AU - Sonin, Dmitry

AU - Hand, Arthur R.

AU - Zarini, Simona

AU - Murphy, Robert C.

AU - Belinsky, Glenn S.

AU - Nakanishi, Masako

AU - Rosenberg, Daniel W.

PY - 2010/6/18

Y1 - 2010/6/18

N2 - Cytosolic phospholipase A2 (cPLA2) is the rate-limiting enzyme responsible for the generation of prostaglandins (PGs), which are bioactive lipids that play critical roles in maintaining gastrointestinal (GI) homeostasis. There has been a long-standing association between administration of cyclooxygenase (COX) inhibitors and GI toxicity. GI injury is thought to be induced by suppressed production of GI-protective PGs as well as direct injury to enterocytes. The present study sought to determine how pansuppression of PG production via a genetic deletion of cPLA2 impacts the susceptibility to COX inhibitor-induced GI injury. A panel of COX inhibitors including celecoxib, rofecoxib, sulindac, and aspirin were administered via diet to cPLA2-/- and cPLA2+/+ littermates. Administration of celecoxib, rofecoxib, and sulindac, but not aspirin, resulted in acute lethality (within 2 weeks) in cPLA2-/- mice, but not in wild-type littermates. Histomorphological analysis revealed severe GI damage following celecoxib exposure associated with acute bacteremia and sepsis. Intestinal PG levels were reduced equivalently in both genotypes following celecoxib exposure, indicating that PG production was not likely responsible for the differential sensitivity. Gene expression profiling in the small intestines of mice identified drug-related changes among a panel of genes including those involved in mitochondrial function in cPLA2-/- mice. Further analysis of enterocytic mitochondria showed abnormal morphology as well as impaired ATP production in the intestines from celecoxib-exposed cPLA2-/- mice. Our data demonstrate that cPLA2 appears to be an important component in conferring protection against COX inhibitor-induced enteropathy, which may be mediated through affects on enterocytic mitochondria.

AB - Cytosolic phospholipase A2 (cPLA2) is the rate-limiting enzyme responsible for the generation of prostaglandins (PGs), which are bioactive lipids that play critical roles in maintaining gastrointestinal (GI) homeostasis. There has been a long-standing association between administration of cyclooxygenase (COX) inhibitors and GI toxicity. GI injury is thought to be induced by suppressed production of GI-protective PGs as well as direct injury to enterocytes. The present study sought to determine how pansuppression of PG production via a genetic deletion of cPLA2 impacts the susceptibility to COX inhibitor-induced GI injury. A panel of COX inhibitors including celecoxib, rofecoxib, sulindac, and aspirin were administered via diet to cPLA2-/- and cPLA2+/+ littermates. Administration of celecoxib, rofecoxib, and sulindac, but not aspirin, resulted in acute lethality (within 2 weeks) in cPLA2-/- mice, but not in wild-type littermates. Histomorphological analysis revealed severe GI damage following celecoxib exposure associated with acute bacteremia and sepsis. Intestinal PG levels were reduced equivalently in both genotypes following celecoxib exposure, indicating that PG production was not likely responsible for the differential sensitivity. Gene expression profiling in the small intestines of mice identified drug-related changes among a panel of genes including those involved in mitochondrial function in cPLA2-/- mice. Further analysis of enterocytic mitochondria showed abnormal morphology as well as impaired ATP production in the intestines from celecoxib-exposed cPLA2-/- mice. Our data demonstrate that cPLA2 appears to be an important component in conferring protection against COX inhibitor-induced enteropathy, which may be mediated through affects on enterocytic mitochondria.

KW - COX inhibitor

KW - Cytosolic phospholipase A

KW - Intestine

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=77955886058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955886058&partnerID=8YFLogxK

U2 - 10.1093/toxsci/kfq184

DO - 10.1093/toxsci/kfq184

M3 - Article

VL - 117

SP - 122

EP - 132

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

ER -